---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000129"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:27:33.967055+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis presents ASCO data: azenosertib+chemo response linked to Cyclin E1

## Summary
- Azenosertib + chemo (paclitaxel, carboplatin, gemcitabine, PLD) shows ORR of 34% across 94 evaluable patients.
- Cyclin E1 IHC+ patients had median PFS 9.86 mo vs 3.25 mo for low (HR 0.37, p=0.0078).
- RP2D set: azenosertib 300 mg QD 5:2 + paclitaxel 80 mg/m2; RP2D with carboplatin 200 mg QD 5:2.
- Phase 3 design proposed comparing azenosertib+chemo vs carboplatin doublet in Cyclin E1+ platinum-sensitive ovarian cancer.
- ZN-d5 (BCL-2) + azenosertib phase 1/2 in AML enrolling; no efficacy data yet.

## SEC filing metadata
- accession: 0001725160-23-000129
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000129/0001725160-23-000129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000129/zntl-20230605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000129
- JSON: https://secwatch.observer/filing/0001725160-23-000129.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.